Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73618913" target="_blank" >RIV/61989592:15110/23:73618913 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.eurekaselect.com/article/123757" target="_blank" >https://www.eurekaselect.com/article/123757</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1871520622666220519102948" target="_blank" >10.2174/1871520622666220519102948</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy

Popis výsledku v původním jazyce

Tumour relapse, chemotherapy resistance, and metastasis continue to be unsolved issues in cancer therapy. A recent approach has been to scrutinise drugs used in the clinic for other illnesses and modify their structure to increase selectivity to cancer cells. Chloroquine (CQ) and hydroxychloroquine (HCQ), known antimalarials, have successfully treated autoimmune and neoplastic diseases. CQ and HCQ, well-known lysosomotropic agents, induce apoptosis, downregulate autophagy, and modify the tumour microenvironment. Moreover, they affect the Toll 9/NF-κB receptor pathway, activate stress response pathways, enhance p53 activity and CXCR4-CXCL12 expression in cancer cells, which would help explain their effects in cancer treatment. These compounds can normalise the tumour associated vasculature, promote the activation of the immune system, change the phenotype of tumour-associated macrophages (from M2 to M1), and stimulate cancer-associated fibroblasts. We aim to review the historical aspects of CQ and its derivatives and the most relevant mechanisms that support the therapeutic use of CQ and HCQ for the treatment of cancer.

Název v anglickém jazyce

Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy

Popis výsledku anglicky

Tumour relapse, chemotherapy resistance, and metastasis continue to be unsolved issues in cancer therapy. A recent approach has been to scrutinise drugs used in the clinic for other illnesses and modify their structure to increase selectivity to cancer cells. Chloroquine (CQ) and hydroxychloroquine (HCQ), known antimalarials, have successfully treated autoimmune and neoplastic diseases. CQ and HCQ, well-known lysosomotropic agents, induce apoptosis, downregulate autophagy, and modify the tumour microenvironment. Moreover, they affect the Toll 9/NF-κB receptor pathway, activate stress response pathways, enhance p53 activity and CXCR4-CXCL12 expression in cancer cells, which would help explain their effects in cancer treatment. These compounds can normalise the tumour associated vasculature, promote the activation of the immune system, change the phenotype of tumour-associated macrophages (from M2 to M1), and stimulate cancer-associated fibroblasts. We aim to review the historical aspects of CQ and its derivatives and the most relevant mechanisms that support the therapeutic use of CQ and HCQ for the treatment of cancer.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molekulární, buněčný a klinický přístup ke zdravému stárnutí</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anti-Cancer Agents in Medicinal Chemistry

ISSN

1871-5206

e-ISSN

1875-5992

Svazek periodika

23

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

23

Strana od-do

1122-1144

Kód UT WoS článku

001025442300003

EID výsledku v databázi Scopus

2-s2.0-85161055349